Data on new Novo Nordisk obesity drug disappoints in trial, stirs worries Lilly gaining edge in sector
Novo Nordisk on Monday revealed data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares ...
Devdiscourse28m
Novo Nordisk's CagriSema Trial Results Fall Short, Market Reacts
Novo Nordisk's obesity drug CagriSema failed to outperform Eli Lilly's Mounjaro in the latest trial, causing a dip in Novo's ...
Fierce Biotech8m
Novo Nordisk links CagriSema to 16% weight loss, sending stock down again
Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...
Investor's Business Daily on MSN31m
Novo Nordisk Dives 8%. Why Eli Lilly Now Has The Upper Hand.
Novo Nordisk stock tumbled Monday after its experimental weight-loss drug failed to top its rival from Eli Lilly in a Phase 3 study.
Novo Nordisk plunges following latest CagriSema data
Novo Nordisk’s stock has dropped around 6.6% in premarket trading Monday following the release of its latest clinical trial data for CagriSema, a treatment for adults with obesity or overweight and ...